HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD)
Enroll HD participant
Capable of consenting or have a legal representative (parent/guardian for juveniles)
Capable of complying with study procedures
Drug trial within 30 days of any sampling visit
Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days)
Antiplatelet or anticoagulant therapy within 14 days
Significant comorbidity
Participants across 8 clinical cohorts will be enrolled at multiple sites up to an estimated minimum of 2500 participants or until the study is terminated by either the Funding Source or Sponsor
Cohort
Prospective
Not listed
8
Trial groupsSee each trial group below.
The primary objective of this study is:
To generate a high quality CSF sample collection for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD.
The secondary objectives of this study are:
To generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development. To collect phenotypic and clinical data for each participant.
Click on the lead sponsor to view all of their trials.
University College, London
Lead sponsor
CHDI Foundation, Inc.
Collaborator
